Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | January 02, 2020 | January 03, 2020 |
| Innoviva, Inc.INVA · Entity 4679 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date January 02, 2020 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 828,791 |
Reported balance
After 2020-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 125,000 · Balance 828,791 F1: Grant of restricted stock units pursuant to the terms of a consulting agreement effective as of January 1, 2020 between the reporting person and the issuer. Assuming continuous service through each vesting date, the restricted stock units vest in 12 approximately equal installments on the last day of each month for 12 months. F2: Includes 2,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan in 2019 through transactions that were exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units pursuant to the terms of a consulting agreement effective as of January 1, 2020 between the reporting person and the issuer. Assuming continuous service through each vesting date, the restricted stock units vest in 12 approximately equal installments on the last day of each month for 12 months.
F2: Includes 2,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan in 2019 through transactions that were exempt under Rule 16b-3(c).
Innoviva, Inc.
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,035 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 9,786 · Balance 45,035 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.99 · Expires 2036-05-03 | Direct | 10,000 |
Reported balance
After 2026-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001193125-26-209003 · ownership.xml · derivative · entry 2 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-05-03 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 9,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209003 · ownership.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,035 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:36 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001104659-25-051749 · tm2515701-1_4seq1.xml · derivative · entry 2 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:36 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051749 · tm2515701-1_4seq1.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,249 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:00 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001104659-24-073454 · tm2417570-5_4seq1.xml · derivative · entry 2 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,833 Underlying: Common Stock · 10,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:00 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 13,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073454 · tm2417570-5_4seq1.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,172 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:58 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001149 · doc4.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,791 F1 · shares: Grant of restricted stock units pursuant to the terms of a consulting agreement effective as of January 1, 2020 between the reporting person and the issuer. Assuming continuous service through each vesting date, the restricted stock units vest in 12 approximately equal installments on the last day of each month for 12 months. F2 · balance_after: Includes 2,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan in 2019 through transactions that were exempt under Rule 16b-3(c). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.69 | $0.00 |
DisclosureSEC source: 0001144204-19-017733 · tv517878_4.xml · derivative · entry 2 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-03-29 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2023. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017733 · tv517878_4.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,791 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2020; March 29, 2021; March 29, 2022; and March 29, 2023. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 20:01 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | PurchaseCommon Stock | 1,200 | $41.77 | $50,123.04 |
DisclosureSEC source: 0001144204-18-039136 · tv498888_4.xml · nonDerivative · entry 2 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,291 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.44 to $42.35, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the price range. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 20:01 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | PurchaseCommon Stock | 1,200 | $41.19 | $49,428.24 |
DisclosureSEC source: 0001144204-18-039136 · tv498888_4.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,091 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.98 to $41.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the price range. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 22:26 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $49.14 | $0.00 |
DisclosureSEC source: 0001144204-18-018344 · tv490033_4.xml · derivative · entry 2 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-29 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, March 29, 2019; and the remaining 75% shall vest in 36 equal monthly installments, with the options becoming fully vested on March 29, 2022. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 22:26 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-018344 · tv490033_4.xml · nonDerivative · entry 1 Small Derek A · CIK 0001613260 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,891 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2019; March 29, 2020; March 29, 2021; and March 29, 2022. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 20:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $25.34 | $0.00 |
DisclosureSEC source: 0001144204-17-018203 · v463068_4.xml · derivative · entry 1 Small Derek A · CIK 0001613260 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-03-29 F1 · derivative.exercise_date: The options vest over two years as follows: 50% shall vest on the first anniversary of the date of grant, March 29, 2018; and the remaining 50% shall vest in 12 equal monthly installments, with the options becoming fully vested on March 29, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.